Cytyc's ThinPrep takes over in Ireland:
This article was originally published in Clinica
Executive Summary
Cytyc has become the exclusive supplier of liquid-based cytology to Ireland's laboratories, after the company's Irish distributor Screenlink clinched a deal with the remaining two laboratories that have yet to be converted to Cytyc's ThinPrep Pap test. Around 250,000 cervical cancer tests are performed in Ireland each year. Currently, 150,000 of these tests are carried out on the Marlborough, Massachusetts company's ThinPrep system. The remaining labs, based in Cork and Galway, are expected to undergo the conversion to ThinPrep in the next few months.
You may also be interested in...
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.